Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Hirsh-Raccah Bruria


 Last updated December 2021 - School of Pharmacy

List of Publications

(1) Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 2021;11(1).

(2) Perlman A, Goldstein R, Choshen Cohen L, Hirsh‑Raccah B, Hakimian D, Matok I, et al. Correction to: Effect of Enzyme‑Inducing Antiseizure Medications on the Risk of Sub‑Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study (CNS Drugs, (2021), 35, 3, (305-316), 10.1007/s40263-021-00795-z). CNS Drugs 2021;35(8):919.

(3) Hirsh Raccah B, Yanovsky A, Treves N, Rotshild V, Renoux C, Danenberg H, et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. Int J Cardiol 2021;335:7-14.

(4) Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al. Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. CNS Drugs 2021;35(3):305-316.

(5) Hirsch A, Wanounou M, Perlman A, Hirsh-Raccah B, Muszkat M. The effect of multidrug exposure on neurological manifestations in carbamazepine intoxication: A nested case-control study. BMC Pharmacol Toxicol 2020;21(1).

(6) Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I. The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database. Int J Obes 2020;44(5):1021-1027.

(7) Hirsh Raccah B, Rottenstreich A, Zacks N, Matok I, Danenberg HD, Pollak A, et al. Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients. J Thromb Thrombolysis 2019;47(4):550-557.

(8) Perlman A, Hochberg-Klein S, Choshen Cohen L, Dagan G, Hirsh-Raccah B, Horwitz E, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis 2019;47(4):590-595.

(9) Kabiri D, Masarwy R, Schachter-Safrai N, Masarwa R, Hirsh Raccah B, Ezra Y, et al. Trial of labor after cesarean delivery in twin gestations: systematic review and meta-analysis. Am J Obstet Gynecol 2019;220(4):336-347.

(10) Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Fisher Negev T, Hochberg-Klein S, et al. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res 2019;8(1).

(11) Hirsh Raccah B, Rottenstreich A, Zacks N, Muszkat M, Matok I, Perlman A, et al. Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. J Thromb Thrombolysis 2018;46(4):521-527.

(12) Raccah BH, Perlman A, Zwas DR, Hochberg-Klein S, Masarwa R, Muszkat M, et al. Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis. Ann Pharmacother 2018;52(11):1135-1142.

(13) Perlman A, Hirsh Raccah B, Matok I, Muszkat M. Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. J Card Fail 2018;24(8):533-536.

(14) Rotshild V, Azoulay L, Zarifeh M, Masarwa R, Hirsh-Raccah B, Perlman A, et al. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies. Drug Saf 2018;41(6):555-564.

(15) Rottenstreich A, Zacks N, Kleinstern G, Raccah BH, Roth B, Da’as N, et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 2018;45(4):543-549.

(16) Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thromb Res 2018;163:190-195.

(17) Gotsman I, Ezra O, Hirsh Raccah B, Admon D, Lotan C, Dekeyser Ganz F. Patient-Specific Tailored Intervention Improves INR Time in Therapeutic Range and INR Variability in Heart Failure Patients. Am J Med 2017;130(8):982-989.

(18) Masarwa R, Paret G, Perlman A, Reif S, Raccah BH, Matok I. Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: A systematic review, meta-analysis, and trial sequential analysis. Crit Care 2017;21(1).

(19) Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M, Matok I. Major Bleeding and Hemorrhagic Stroke with Direct Oral Anticoagulants in Patients with Renal Failure Systematic Review and Meta-Analysis of Randomized Trials. Chest 2016;149(6):1516-1524.

(20) Raccah BH, Shalit M, Danenberg HD. Allergic reaction to prasugrel and cross-reactivity with clopidogrel. Int J Cardiol 2012;157(3):e48-e49.